DYNAMIC CHANGES IN THE CONCENTRATION OF ANTI-SARS-COV-2 ANTIBODIES WITHIN 12 MONTHS AFTER RECOVERY FROM COVID-19

被引:0
|
作者
Mayanskiy, N. A. [1 ]
Brzhozovskaya, E. A. [1 ]
Stoyanova, S. S. [1 ]
Frolkov, A., V [1 ]
Lebedin, Yu S. [2 ]
机构
[1] Pirogov Russian Natl Res Med Univ, Moscow, Russia
[2] XEMA LLC, Moscow, Russia
来源
BULLETIN OF RUSSIAN STATE MEDICAL UNIVERSITY | 2022年 / 01期
关键词
SARS-CoV-2; anti-RBD IgG; dynamic changes; concentration; BAU/mL;
D O I
10.24075/brsmu.2022.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Generation and maintenance of immunity to SARS-CoV-2 is essential for overcoming the pandemic of the novel coronavirus infection COVID-19. The study was aimed to assess the dynamic changes in the levels of IgG antibodies against the SARS-CoV-2 receptor-binding domain (RBD) with the use of the enzyme-linked immunosorbent assay (ELISA) kits, calibrated using the International Standard for anti-SARS-CoV-2 immunoglobulin (IS-SARS-CoV-2). The concentrations of anti-RBD-IgG were measured in the cohort of individuals, who had recovered from COVID-19, with an interval of a month for 6 months, and at a time point of 12 months, using the ELISA kits, calibrated with the use of IS-SARS-CoV-2; the results were expressed in binding antibody units (BAU) per 1 mL. A total of 97 blood serum samples, obtained from 20 individuals with SARS-CoV-2 infection, confirmed by PCR, were collected. The geometric mean titer (GMT) of anti-RBD-IgG was 433 BAU/mL (range 36-25,900 BAU/mL) within a month after the infection. The concentration of anti-RBD-IgG gradually decreased with time and reached the GMT value of 68 BAU/mL by the 12th month; anti-RBD-IgG persisted in 13 individuals (93%) out of 14, examined 12 months after the infection. The standardized quantitative serological data play a vital part in monitoring the immune response and make in easier to compare the studies, providing the basis for seeking the common serological correlate of the protective immunity to SARS-CoV-2.
引用
收藏
页码:12 / 14
页数:3
相关论文
共 50 条
  • [1] Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
    Kening Li
    Bin Huang
    Min Wu
    Aifang Zhong
    Lu Li
    Yun Cai
    Zhihua Wang
    Lingxiang Wu
    Mengyan Zhu
    Jie Li
    Ziyu Wang
    Wei Wu
    Wanlin Li
    Bakwatanisa Bosco
    Zhenhua Gan
    Qinghua Qiao
    Jian Wu
    Qianghu Wang
    Shukui Wang
    Xinyi Xia
    Nature Communications, 11
  • [2] Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19
    Li, Kening
    Huang, Bin
    Wu, Min
    Zhong, Aifang
    Li, Lu
    Cai, Yun
    Wang, Zhihua
    Wu, Lingxiang
    Zhu, Mengyan
    Li, Jie
    Wang, Ziyu
    Wu, Wei
    Li, Wanlin
    Bosco, Bakwatanisa
    Gan, Zhenhua
    Qiao, Qinghua
    Wu, Jian
    Wang, Qianghu
    Wang, Shukui
    Xia, Xinyi
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [3] Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19
    Terpos, Evangelos
    Mentis, Andreas
    Dimopoulos, Meletios A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17): : 1695 - 1695
  • [4] Seroprevalence of anti-SARS-CoV-2 antibodies in Japanese COVID-19 patients
    Hiki, Makoto
    Tabe, Yoko
    Ai, Tomohiko
    Matsue, Yuya
    Harada, Norihiro
    Sugimoto, Kiichi
    Matsushita, Yasushi
    Matsushita, Masakazu
    Wakita, Mitsuru
    Misawa, Shigeki
    Idei, Mayumi
    Miida, Takashi
    Tamura, Naoto
    Takahashi, Kazuhisa
    Naito, Toshio
    PLOS ONE, 2021, 16 (04):
  • [5] Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects
    Huynh, Angela
    Arnold, Donald M.
    Smith, James W.
    Moore, Jane C.
    Zhang, Ali
    Chagla, Zain
    Harvey, Bart J.
    Stacey, Hannah D.
    Ang, Jann C.
    Clare, Rumi
    Ivetic, Nikola
    Chetty, Vasudhevan T.
    Bowdish, Dawn M. E.
    Miller, Matthew S.
    Kelton, John G.
    Nazy, Ishac
    VIRUSES-BASEL, 2021, 13 (04):
  • [6] Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19 REPLY
    Yang, Otto O.
    Ibarrondo, F. Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (17): : 1697 - 1698
  • [7] ANTI-SARS-COV-2 ANTIBODIES AND AUTOANTIBODIES IN COVID-19 PATIENTS SURVIVED AFTER ICU ADMISSION, 6 MONTHS LATER
    Bitzogli, K.
    Magira, E.
    Chatzis, L.
    Jahaj, E.
    Alexopoulos, H.
    Dalakas, M.
    Kotanidou, A.
    Tzioufas, A.
    Vlachoyiannopoulos, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1381 - 1381
  • [8] Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19
    Borsche, Max
    Reichel, Dirk
    Fellbrich, Anja
    Lixenfeld, Anne S.
    Rahmoeller, Johann
    Vollstedt, Eva-Juliane
    Foeh, Bandik
    Balck, Alexander
    Klein, Christine
    Ehlers, Marc
    Moser, Andreas
    NEUROLOGICAL RESEARCH AND PRACTICE, 2021, 3 (01):
  • [9] Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19
    Max Borsche
    Dirk Reichel
    Anja Fellbrich
    Anne S. Lixenfeld
    Johann Rahmöller
    Eva-Juliane Vollstedt
    Bandik Föh
    Alexander Balck
    Christine Klein
    Marc Ehlers
    Andreas Moser
    Neurological Research and Practice, 3
  • [10] Anti-SARS-COV-2 and self-reactive antibodies in neuropsychiatric COVID-19
    Bartley, Christopher
    Ngo, Thomas
    Dandekar, Ravi
    Song, Eric
    Alvarenga, Bonny
    Johns, Claire
    Wietstock, Sharon
    Zamecnik, Colin
    Rajan, Jayant
    Derisi, Joseph
    Spudich, Serena
    Farhadian, Shelli
    Pleasure, Samuel
    Wilson, Michael
    CHEMICAL SENSES, 2022, 47